文献速递免疫规划慢病防控与筛查

肯尼亚HIV感染儿童四价HPV疫苗48个月抗体反应

Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
PubMed 文献 · Vaccine · 2021-01-21

研究对肯尼亚178名9-14岁HIV感染儿童接种三剂四价HPV疫苗后随访4年,176人纳入延伸随访。结果显示48个月时HPV-6/11/16/18血清阳性率分别为83%、80%、90%、77%,抗体滴度在24至48个月间趋于平台;接种时HIV病毒载量检测不到者抗体滴度持续较高。

要点

  • HIV感染儿童接种四价HPV疫苗后48个月仍保持较高血清阳性率。
  • 抗体滴度在24至48个月间趋于平台,未见持续下降。
  • 接种时HIV病毒载量检测不到者抗体滴度更高。

核心结论

  • HIV感染儿童接种四价HPV疫苗后可能保留长期抗体反应。
  • 需进一步研究低抗体水平是否仍能预防HPV感染。

研究设计与样本

  • 对178名既往接种三剂四价HPV疫苗的9-14岁HIV感染儿童进行延伸随访,176人纳入4年随访。
  • 于首剂后24、36、48个月用总IgG免疫测定法检测HPV-6/11/16/18抗体。

主要发现

  • 48个月时HPV血清阳性率:HPV-6为83%,HPV-11为80%,HPV-16为90%,HPV-18为77%。
  • 24至48个月间HPV特异性抗体平均log10滴度呈平台。
  • 接种时HIV病毒载量<40 copies/mL者抗体滴度在48个月内持续高于可检测病毒载量者。

关键数值与推荐

  • 再入组时中位年龄14岁(范围11-17),167人(95%)接受抗逆转录病毒治疗,110人(66%)血浆HIV RNA<40 copies/mL。

临床怎么用

  • 支持HIV感染儿童按程序接种四价HPV疫苗以维持长期抗体反应。

局限性

  • 未确定低抗体水平是否提供HPV感染保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: HIV infected children remain at increased risk of HPV associated malignancies as they initiate sexual activity. Though they mount a vigorous immune response to the quadrivalent human papillomavirus (QHPV-6, -11,-16, and -18; Gardasil®) vaccine, durability of the immune response is uncertain. We assessed antibody responses to HPV 6, -11, -16 and -18 for up to 48 months following administration of quadrivalent human papillomavirus vaccine in HIV-infected girls and boys ages 9-14 years in Kenya. DESIGN: Of 178 girls and boys who had previously received three doses of the quadrivalent HPV vaccine, 176 enrolled into extended follow up for 4 years. HPV antibodies to -6, -11, -16 and -18 were measured at 24, 36 and 48 months after the first vaccine dose using the total immunoglobulin G immunoassay (IgG LIA). We evaluated the magnitude and trend in HPV vaccine response and the effect of plasma HIV-1 RNA on HPV vaccine response from month 24 to month 48 of follow up. RESULTS: At re-enrollment, 24 months after initial vaccination, median age of participants was 14 years (range 11-17); 167 (95%) were receiving antiretroviral therapy and 110 (66%) had plasma HIV RNA < 40 copies/mL. The rate of HPV seropositivity at 48 months was 83% for HPV-6; 80% for HPV-11; 90% for HPV-16; and 77% for HPV-18. There was a plateau in mean log10 HPV-specific antibody titer between month 24 and 48. The mean log10 HPV-type specific antibody titer for children with undetectable HIV viral load (<40) at the time of vaccination consistently remained higher for the 48 months of follow up compared to children with detectable viral load. CONCLUSION: Children with HIV infection may retain long term antibody response following HPV immunization. Further work to define whether HIV-infected children are protected from HPV acquisition with low levels of HPV antibodies is needed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mugo N, Eckert LO, Odero L, et al. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa. Vaccine. 2021. PMID: 33485644. doi:10.1016/j.vaccine.2020.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。